Sandoz settles states' antitrust claims for $400 million
According to MLex, Sandoz will hand over $400 million to settle claims filed by U.S. states and territories accusing the generic-drug manufacturer of taking part in arrangements designed to drive up the cost of medicines and reduce competition. The payment closes out those allegations on financial terms, resolving accusations that the firm acted to limit rivalry within the generic-drug sector.[S1]
The settlement is part of a broader multistate antitrust effort targeting generic-drug pricing practices. Pennsylvania is set to receive $14.8 million under the deal, according to MyChesCo.[S1][S2]
Pennsylvania and New York move on settlement funds
Pennsylvania's share of the settlement is $14.8 million, MyChesCo reported. The allocation reflects how the $400 million resolution is distributed among participating states and territories.[S2]
Understand this article deeper
In New York, the attorney general is advising residents to determine whether they qualify for money back on generic-drug prescriptions, the Utica Observer Dispatch reported. The notice points consumers toward potential refunds connected to the settlement.[S3]
